 Sunny Linnebur
Concepts (322)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Geriatric Nursing | 4 | 2020 | 17 | 2.340 |
Why?
| | Geriatrics | 4 | 2019 | 69 | 1.610 |
Why?
| | Health Services for the Aged | 6 | 2018 | 70 | 1.250 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1395 | 1.240 |
Why?
| | Polypharmacy | 6 | 2023 | 74 | 0.980 |
Why?
| | Nursing Homes | 7 | 2022 | 138 | 0.950 |
Why?
| | Anticoagulants | 3 | 2018 | 550 | 0.900 |
Why?
| | Prescription Drugs | 3 | 2012 | 116 | 0.790 |
Why?
| | Pharmacists | 8 | 2021 | 234 | 0.780 |
Why?
| | Aged, 80 and over | 27 | 2020 | 6347 | 0.770 |
Why?
| | Aging | 4 | 2020 | 1618 | 0.750 |
Why?
| | Aged | 38 | 2021 | 19074 | 0.740 |
Why?
| | Vitamin D Deficiency | 4 | 2012 | 158 | 0.700 |
Why?
| | Vitamin D | 5 | 2016 | 341 | 0.660 |
Why?
| | Bone Diseases | 1 | 2020 | 57 | 0.660 |
Why?
| | Muscular Diseases | 1 | 2020 | 104 | 0.650 |
Why?
| | Societies, Medical | 2 | 2019 | 664 | 0.640 |
Why?
| | Hyponatremia | 2 | 2016 | 37 | 0.630 |
Why?
| | Medication Therapy Management | 3 | 2023 | 67 | 0.620 |
Why?
| | Vitamin K | 1 | 2018 | 42 | 0.590 |
Why?
| | Automobile Driving | 1 | 2019 | 128 | 0.580 |
Why?
| | Warfarin | 2 | 2009 | 135 | 0.580 |
Why?
| | Education, Pharmacy | 4 | 2017 | 123 | 0.580 |
Why?
| | Safety | 1 | 2019 | 298 | 0.580 |
Why?
| | Interprofessional Relations | 1 | 2019 | 249 | 0.560 |
Why?
| | Osteoporosis | 2 | 2010 | 226 | 0.540 |
Why?
| | Self Report | 2 | 2017 | 696 | 0.530 |
Why?
| | Chemical and Drug Induced Liver Injury | 2 | 2010 | 125 | 0.520 |
Why?
| | Bupropion | 1 | 2016 | 39 | 0.520 |
Why?
| | Curriculum | 4 | 2019 | 819 | 0.490 |
Why?
| | Humans | 68 | 2023 | 114705 | 0.490 |
Why?
| | Internet | 1 | 2019 | 596 | 0.480 |
Why?
| | Health Literacy | 1 | 2016 | 164 | 0.460 |
Why?
| | Health Status | 1 | 2019 | 722 | 0.460 |
Why?
| | Antidepressive Agents | 1 | 2016 | 195 | 0.460 |
Why?
| | Health Personnel | 2 | 2019 | 574 | 0.460 |
Why?
| | Vitamins | 3 | 2016 | 151 | 0.450 |
Why?
| | Drug Therapy | 3 | 2017 | 76 | 0.450 |
Why?
| | Long-Term Care | 3 | 2022 | 78 | 0.420 |
Why?
| | Delivery of Health Care | 1 | 2020 | 833 | 0.420 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 975 | 0.410 |
Why?
| | Cross Infection | 2 | 2011 | 197 | 0.410 |
Why?
| | Urinary Retention | 1 | 2012 | 19 | 0.410 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 429 | 0.400 |
Why?
| | Cholinergic Antagonists | 1 | 2012 | 27 | 0.400 |
Why?
| | Physicians | 2 | 2020 | 772 | 0.400 |
Why?
| | Prostatic Hyperplasia | 1 | 2012 | 38 | 0.390 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 63 | 0.390 |
Why?
| | Pragmatic Clinical Trials as Topic | 2 | 2022 | 47 | 0.390 |
Why?
| | Pharmacy Service, Hospital | 2 | 2019 | 83 | 0.390 |
Why?
| | Drug Approval | 1 | 2012 | 78 | 0.390 |
Why?
| | Health Communication | 1 | 2012 | 40 | 0.380 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2012 | 47 | 0.380 |
Why?
| | Students, Pharmacy | 3 | 2017 | 98 | 0.370 |
Why?
| | Grifola | 1 | 2009 | 1 | 0.340 |
Why?
| | Herb-Drug Interactions | 1 | 2009 | 4 | 0.340 |
Why?
| | International Normalized Ratio | 1 | 2009 | 45 | 0.340 |
Why?
| | Central Nervous System Agents | 1 | 2009 | 5 | 0.340 |
Why?
| | Depression | 3 | 2018 | 1134 | 0.340 |
Why?
| | Blood Pressure | 1 | 2015 | 1538 | 0.330 |
Why?
| | Renal Insufficiency | 2 | 2016 | 137 | 0.330 |
Why?
| | Patient Education as Topic | 3 | 2012 | 680 | 0.330 |
Why?
| | Pneumonia | 2 | 2011 | 568 | 0.330 |
Why?
| | Fractures, Bone | 3 | 2016 | 367 | 0.320 |
Why?
| | Pain | 4 | 2018 | 705 | 0.320 |
Why?
| | Central Nervous System Diseases | 1 | 2009 | 61 | 0.320 |
Why?
| | Male | 31 | 2020 | 55607 | 0.320 |
Why?
| | Drug Monitoring | 1 | 2010 | 184 | 0.310 |
Why?
| | Educational Measurement | 4 | 2017 | 243 | 0.300 |
Why?
| | Female | 32 | 2020 | 59521 | 0.300 |
Why?
| | Hypertension | 1 | 2015 | 1056 | 0.290 |
Why?
| | Drug Interactions | 4 | 2018 | 338 | 0.290 |
Why?
| | Faculty, Dental | 1 | 2007 | 8 | 0.280 |
Why?
| | Bone and Bones | 1 | 2010 | 279 | 0.280 |
Why?
| | Dental Care for Chronically Ill | 1 | 2007 | 11 | 0.280 |
Why?
| | Erectile Dysfunction | 1 | 2006 | 38 | 0.270 |
Why?
| | Education, Dental | 1 | 2007 | 24 | 0.270 |
Why?
| | Dietary Supplements | 1 | 2010 | 460 | 0.270 |
Why?
| | Testis | 1 | 2007 | 133 | 0.260 |
Why?
| | Urinary Tract Infections | 2 | 2019 | 134 | 0.260 |
Why?
| | Cognitive Dysfunction | 2 | 2021 | 284 | 0.260 |
Why?
| | Community Pharmacy Services | 1 | 2005 | 42 | 0.250 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 24 | 0.240 |
Why?
| | Patient Advocacy | 1 | 2005 | 66 | 0.240 |
Why?
| | United States | 8 | 2020 | 12186 | 0.240 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2016 | 299 | 0.230 |
Why?
| | Diphosphonates | 1 | 2004 | 51 | 0.230 |
Why?
| | Nitrofurantoin | 1 | 2004 | 7 | 0.230 |
Why?
| | Fluconazole | 1 | 2004 | 16 | 0.230 |
Why?
| | Research Design | 1 | 2009 | 928 | 0.220 |
Why?
| | Cholecalciferol | 2 | 2016 | 47 | 0.220 |
Why?
| | Chronic Disease | 4 | 2019 | 1578 | 0.220 |
Why?
| | Antifungal Agents | 1 | 2004 | 128 | 0.210 |
Why?
| | Smoking Cessation | 1 | 2006 | 374 | 0.210 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 373 | 0.210 |
Why?
| | Colorado | 8 | 2018 | 4100 | 0.210 |
Why?
| | Age Factors | 5 | 2015 | 2894 | 0.200 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1481 | 0.200 |
Why?
| | Cyclohexanols | 1 | 2002 | 9 | 0.200 |
Why?
| | Professional Role | 4 | 2018 | 149 | 0.200 |
Why?
| | Research | 1 | 2005 | 394 | 0.200 |
Why?
| | Vaginal Diseases | 1 | 2002 | 17 | 0.200 |
Why?
| | Prevalence | 4 | 2017 | 2251 | 0.200 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2002 | 38 | 0.200 |
Why?
| | Middle Aged | 13 | 2020 | 26738 | 0.190 |
Why?
| | Nonprescription Drugs | 2 | 2016 | 68 | 0.190 |
Why?
| | Administration, Oral | 3 | 2018 | 728 | 0.190 |
Why?
| | United States Food and Drug Administration | 2 | 2012 | 172 | 0.190 |
Why?
| | Ergocalciferols | 2 | 2012 | 11 | 0.190 |
Why?
| | Medication Adherence | 3 | 2017 | 536 | 0.180 |
Why?
| | Retrospective Studies | 13 | 2021 | 12556 | 0.180 |
Why?
| | Self Care | 2 | 2014 | 349 | 0.170 |
Why?
| | Alzheimer Disease | 1 | 2005 | 442 | 0.170 |
Why?
| | Methenamine | 1 | 2019 | 4 | 0.170 |
Why?
| | Diet | 1 | 2007 | 1080 | 0.170 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2019 | 13 | 0.170 |
Why?
| | Smoking | 1 | 2006 | 1383 | 0.170 |
Why?
| | Patients | 2 | 2011 | 163 | 0.160 |
Why?
| | Education, Continuing | 1 | 2019 | 39 | 0.160 |
Why?
| | Sexism | 1 | 2019 | 44 | 0.160 |
Why?
| | Physicians, Women | 1 | 2019 | 55 | 0.160 |
Why?
| | Pharmacy | 1 | 2019 | 28 | 0.160 |
Why?
| | Transitional Care | 1 | 2019 | 34 | 0.150 |
Why?
| | Melatonin | 1 | 2019 | 106 | 0.150 |
Why?
| | Recreation | 1 | 2018 | 21 | 0.150 |
Why?
| | Patient Transfer | 1 | 2020 | 143 | 0.150 |
Why?
| | Proton Pump Inhibitors | 1 | 2019 | 96 | 0.150 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 951 | 0.150 |
Why?
| | Drug Prescriptions | 2 | 2010 | 239 | 0.150 |
Why?
| | Hemorrhage | 1 | 2002 | 620 | 0.150 |
Why?
| | Independent Living | 1 | 2018 | 84 | 0.150 |
Why?
| | Lung Diseases | 1 | 2004 | 701 | 0.140 |
Why?
| | Medication Reconciliation | 2 | 2019 | 25 | 0.140 |
Why?
| | Problem-Based Learning | 2 | 2017 | 78 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 21 | 0.140 |
Why?
| | Guideline Adherence | 2 | 2011 | 490 | 0.140 |
Why?
| | Cohort Studies | 3 | 2015 | 4895 | 0.140 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 48 | 0.140 |
Why?
| | Health Education | 2 | 2016 | 323 | 0.140 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 213 | 0.130 |
Why?
| | Leadership | 1 | 2019 | 292 | 0.130 |
Why?
| | Patient-Centered Care | 2 | 2023 | 473 | 0.130 |
Why?
| | Refuse Disposal | 1 | 2016 | 2 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2019 | 233 | 0.130 |
Why?
| | Ibuprofen | 1 | 2016 | 75 | 0.130 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 1013 | 0.130 |
Why?
| | Dementia | 1 | 2018 | 187 | 0.130 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1079 | 0.130 |
Why?
| | Marijuana Use | 1 | 2018 | 167 | 0.130 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 39 | 0.120 |
Why?
| | Faculty, Medical | 1 | 2017 | 228 | 0.120 |
Why?
| | Sodium | 1 | 2016 | 183 | 0.120 |
Why?
| | Child Health | 1 | 2016 | 127 | 0.120 |
Why?
| | Kansas | 2 | 2011 | 29 | 0.120 |
Why?
| | Missouri | 2 | 2011 | 61 | 0.120 |
Why?
| | Cognition Disorders | 1 | 2018 | 476 | 0.120 |
Why?
| | Ambulatory Care | 3 | 2008 | 478 | 0.120 |
Why?
| | Blood Glucose | 2 | 2014 | 1828 | 0.120 |
Why?
| | Patient Care Team | 2 | 2011 | 517 | 0.120 |
Why?
| | Creatinine | 2 | 2007 | 425 | 0.110 |
Why?
| | Atrial Fibrillation | 1 | 2018 | 322 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 165 | 0.110 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 28 | 0.110 |
Why?
| | Priapism | 1 | 2013 | 10 | 0.110 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 29 | 0.110 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.110 |
Why?
| | Proline | 1 | 2013 | 72 | 0.110 |
Why?
| | Nursing Staff | 2 | 2010 | 38 | 0.110 |
Why?
| | Hoarding | 1 | 2012 | 2 | 0.100 |
Why?
| | Electronic Health Records | 3 | 2014 | 800 | 0.100 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 319 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 822 | 0.100 |
Why?
| | Accidental Falls | 2 | 2016 | 151 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 2 | 2011 | 1177 | 0.100 |
Why?
| | Kidney | 1 | 2019 | 1188 | 0.100 |
Why?
| | Teaching | 1 | 2014 | 213 | 0.100 |
Why?
| | Assisted Living Facilities | 2 | 2016 | 9 | 0.100 |
Why?
| | Prognosis | 1 | 2019 | 3330 | 0.100 |
Why?
| | Education, Nursing, Continuing | 1 | 2011 | 37 | 0.100 |
Why?
| | Adult | 8 | 2020 | 30553 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2014 | 341 | 0.090 |
Why?
| | Stakeholder Participation | 2 | 2022 | 73 | 0.090 |
Why?
| | Administration, Inhalation | 1 | 2012 | 641 | 0.090 |
Why?
| | Glucosamine | 1 | 2010 | 12 | 0.090 |
Why?
| | Mass Screening | 3 | 2018 | 1006 | 0.090 |
Why?
| | Chondroitin Sulfates | 1 | 2010 | 33 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2014 | 2096 | 0.090 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 42 | 0.080 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 96 | 0.080 |
Why?
| | Piracetam | 1 | 2009 | 15 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 718 | 0.080 |
Why?
| | Stroke | 1 | 2018 | 1022 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 90 | 0.080 |
Why?
| | Infection Control | 1 | 2010 | 135 | 0.080 |
Why?
| | Delphi Technique | 1 | 2009 | 160 | 0.080 |
Why?
| | Hip Fractures | 1 | 2010 | 75 | 0.080 |
Why?
| | Immunization Programs | 1 | 2010 | 205 | 0.080 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 21 | 0.070 |
Why?
| | Conflict of Interest | 1 | 2009 | 119 | 0.070 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 4624 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2009 | 179 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 668 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2010 | 303 | 0.070 |
Why?
| | Decision Making | 2 | 2011 | 782 | 0.070 |
Why?
| | Heptanoic Acids | 1 | 2007 | 60 | 0.070 |
Why?
| | Nutrition Policy | 1 | 2007 | 54 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1448 | 0.070 |
Why?
| | Simvastatin | 1 | 2007 | 59 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 82 | 0.070 |
Why?
| | Inpatients | 1 | 2010 | 380 | 0.070 |
Why?
| | Orthodontics, Corrective | 1 | 2006 | 7 | 0.070 |
Why?
| | Serum Albumin | 1 | 2007 | 137 | 0.070 |
Why?
| | Premedication | 1 | 2006 | 36 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 4410 | 0.060 |
Why?
| | Isoxazoles | 1 | 2006 | 51 | 0.060 |
Why?
| | Pyrroles | 1 | 2007 | 181 | 0.060 |
Why?
| | Tobacco Products | 1 | 2006 | 98 | 0.060 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 47 | 0.060 |
Why?
| | Life Expectancy | 1 | 2005 | 51 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 102 | 0.060 |
Why?
| | Caregivers | 1 | 2011 | 717 | 0.060 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2005 | 79 | 0.060 |
Why?
| | Medical Records Systems, Computerized | 1 | 2005 | 88 | 0.060 |
Why?
| | Influenza, Human | 1 | 2010 | 546 | 0.060 |
Why?
| | Communication | 3 | 2016 | 744 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1183 | 0.060 |
Why?
| | Heart Failure | 1 | 2017 | 1945 | 0.060 |
Why?
| | Pain, Postoperative | 1 | 2006 | 191 | 0.060 |
Why?
| | Onychomycosis | 1 | 2004 | 2 | 0.060 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 53 | 0.060 |
Why?
| | Palliative Care | 1 | 2010 | 644 | 0.060 |
Why?
| | Outpatients | 1 | 2007 | 326 | 0.060 |
Why?
| | Risk Factors | 2 | 2007 | 8632 | 0.060 |
Why?
| | Quality of Life | 2 | 2023 | 2353 | 0.050 |
Why?
| | Patient Discharge | 2 | 2020 | 773 | 0.050 |
Why?
| | Time Factors | 2 | 2011 | 6116 | 0.050 |
Why?
| | Hematologic Diseases | 1 | 2004 | 55 | 0.050 |
Why?
| | Rheumatic Diseases | 1 | 2004 | 49 | 0.050 |
Why?
| | Algorithms | 1 | 2010 | 1470 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 620 | 0.050 |
Why?
| | Child | 2 | 2023 | 18420 | 0.050 |
Why?
| | Sulfonamides | 1 | 2006 | 445 | 0.050 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2002 | 11 | 0.050 |
Why?
| | Menstruation | 1 | 2002 | 35 | 0.050 |
Why?
| | Health Care Costs | 1 | 2005 | 381 | 0.050 |
Why?
| | Pharmaceutical Services | 2 | 2016 | 77 | 0.050 |
Why?
| | Hospitalization | 1 | 2010 | 1752 | 0.050 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 14 | 0.050 |
Why?
| | Liver Diseases | 1 | 2004 | 255 | 0.050 |
Why?
| | Adolescent | 4 | 2023 | 17853 | 0.050 |
Why?
| | Calcium | 1 | 2007 | 1108 | 0.050 |
Why?
| | Nervous System Diseases | 1 | 2004 | 256 | 0.050 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 771 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1842 | 0.040 |
Why?
| | Biomarkers | 1 | 2010 | 3408 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 932 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2019 | 140 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2002 | 332 | 0.040 |
Why?
| | Anxiety | 2 | 2018 | 840 | 0.040 |
Why?
| | Protons | 1 | 2019 | 73 | 0.040 |
Why?
| | Prospective Studies | 2 | 2007 | 6220 | 0.040 |
Why?
| | Healthcare Financing | 1 | 2018 | 6 | 0.040 |
Why?
| | Guidelines as Topic | 2 | 2010 | 243 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2016 | 1660 | 0.040 |
Why?
| | Geriatric Assessment | 1 | 2018 | 176 | 0.040 |
Why?
| | Nephrology Nursing | 1 | 2016 | 5 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2019 | 356 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 604 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 233 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1373 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 2017 | 159 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2016 | 121 | 0.030 |
Why?
| | Patient Readmission | 1 | 2020 | 610 | 0.030 |
Why?
| | Obesity | 1 | 2007 | 2508 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2018 | 927 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2097 | 0.030 |
Why?
| | Sleep | 1 | 2019 | 632 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2017 | 298 | 0.030 |
Why?
| | Medicare | 1 | 2018 | 665 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 61 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2019 | 9088 | 0.030 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 1727 | 0.030 |
Why?
| | Comprehension | 1 | 2014 | 156 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1342 | 0.030 |
Why?
| | Drug Evaluation | 1 | 2012 | 77 | 0.020 |
Why?
| | Educational Status | 1 | 2014 | 412 | 0.020 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2011 | 10 | 0.020 |
Why?
| | Electronic Mail | 1 | 2011 | 54 | 0.020 |
Why?
| | Personal Autonomy | 1 | 2011 | 39 | 0.020 |
Why?
| | Pharmacies | 1 | 2011 | 32 | 0.020 |
Why?
| | Complementary Therapies | 1 | 2011 | 72 | 0.020 |
Why?
| | Decision Trees | 1 | 2010 | 81 | 0.020 |
Why?
| | Disclosure | 1 | 2011 | 101 | 0.020 |
Why?
| | Midwestern United States | 1 | 2010 | 38 | 0.020 |
Why?
| | Medical Informatics | 1 | 2011 | 90 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2009 | 4411 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 893 | 0.020 |
Why?
| | Young Adult | 2 | 2017 | 10471 | 0.020 |
Why?
| | Massage | 1 | 2010 | 42 | 0.020 |
Why?
| | Child, Preschool | 1 | 2023 | 9118 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 1820 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2014 | 387 | 0.020 |
Why?
| | Medication Errors | 1 | 2010 | 88 | 0.020 |
Why?
| | Epilepsies, Partial | 1 | 2009 | 29 | 0.020 |
Why?
| | Primary Health Care | 1 | 2018 | 1514 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 238 | 0.020 |
Why?
| | Self Administration | 1 | 2008 | 122 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 583 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 117 | 0.020 |
Why?
| | Oxycodone | 1 | 2008 | 44 | 0.020 |
Why?
| | Fentanyl | 1 | 2008 | 65 | 0.020 |
Why?
| | Pain Management | 1 | 2010 | 288 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 159 | 0.020 |
Why?
| | Methadone | 1 | 2008 | 77 | 0.020 |
Why?
| | Morphine | 1 | 2008 | 121 | 0.020 |
Why?
| | Orthodontic Wires | 1 | 2006 | 5 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2009 | 350 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 385 | 0.020 |
Why?
| | Pain Measurement | 1 | 2006 | 444 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1214 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 1715 | 0.010 |
Why?
|
|
Linnebur's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|